LTR Pharma fulfils first US ROXUS prescriptions as SPONTAN Phase II report completes FDA dataset
LTP: $0.440 +0.00% · MC: $86M
LTR Pharma says its first patient-specific ROXUS prescriptions were fulfilled in the US after quarter-end, following agreements with telehealth platform Shed and Strive Pharmacy. A final Phase II report confirmed SPONTAN’s six-fold faster absorption than oral vardenafil tablets and completed its FDA pharmacokinetic dataset; a Phase III study is targeted to start in the first half of 2027. The company reported approximately A$18 million in cash and no debt at quarter-end, with net operating cash outflow of approximately A$2 million.

Comments